Lamivudine/tenofovir disoproxil (3TC/TDF), sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb). It contains lamivudine and tenofovir disoproxil. It is taken by mouth. Lamivudine/tenofovir was approved for medical use in the United States in February 2018.
References
Further reading "WHO Public Assessment Report: HA414 - Lamivudine/Tenofovir disoproxil fumarate - 300mg/300mg - Tablets - Mylan Laboratories Ltd - India". World Health Organization (WHO). Archived from the original on 26 March 2020.


